Mono-Femara

BELIGAS PHARMACEUTICALS MONO-FEMARA

Mono-Femara, a triumph of pharmaceutical precision by Beligas Pharmaceuticals, is defined by its cornerstone ingredient, Letrozole 2.5 mg. This medication takes center stage in regulating hormonal imbalances.

DRUG COMPOSITION

Each Mono-Femara tablet encapsulates 2.5 mg of Letrozole, a potent aromatase inhibitor heralding control over estrogen levels.

PHARMACEUTICAL FORM

Mono-Femara manifests as oral tablets, ensuring precise dosage administration and convenience.

PHARMACEUTICAL GROUP AND ATC CODE

Pharmaceutical Group: Antineoplastic and Immunomodulating Agents
ATC Code: L02BG04 (Letrozole)

PHARMACOLOGICAL PROPERTIES

Letrozole, an aromatase inhibitor, impedes estrogen synthesis, proving efficacious in hormone-sensitive conditions.

PROFILE

• Chemical name: 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
• Chemical formula: C17H11N5
• Percentage of anabolic activity: Not a steroid
• Percentage of androgenic activity: Not a steroid
• Active half life: 2 days
• Recommended dosage: 0.5-2.5 mg/day
• Acne: no
• Bloating (water retention): no
• HBR: no
• Hepatic toxicity: no
• Aromatization: Inhibits aromatase, preventing estrogen conversion

THERAPEUTICAL INDICATIONS

Mono-Femara finds its therapeutic utility in:

• Treating hormone receptor-positive breast cancer in postmenopausal women.
• Managing fertility issues by inducing ovulation in certain cases.

DOSES AND METHOD OF ADMINISTRATION

Commence with 2.5 mg once daily. Adjust dosage based on individual response and specific indications.

CYCLE/STACKING

Solo Cycle:

• Dosage: Initiate with 2.5 mg/day.
• Cycle Length: Tailor the duration as per medical guidance.

Cutting Cycle:

• Mono-Femara plays a vital role in mitigating estrogen-related side effects during cutting cycles.
• Stacking: Combine with appropriate steroids under professional supervision.

Bulking Cycle:

• Limited application in bulking cycles; primarily employed for estrogen control.
• Stacking: Combine with suitable compounds for synergy.

POST CYCLE THERAPY

Administered post anabolic steroid use to counteract estrogen rebound. Dosage: Individualized; commonly 2.5 mg/day.

SIDE EFFECTS

Potential side effects may include hot flashes, joint pain, and fatigue. Monitor and report any adverse reactions promptly.

CONTRAINDICATIONS

Mono-Femara is contraindicated in premenopausal women, individuals with hypersensitivity to Letrozole, and severe liver impairment.

OVERDOSE

In case of suspected overdose, seek immediate medical attention. Symptoms may include dizziness and fainting.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Exercise caution in patients with liver disorders. Regular monitoring of bone density may be required.

INTERACTIONS WITH OTHER DRUGS

Letrozole may interact with certain medications. Consult with a healthcare professional to avoid potential drug interactions.

PRESENTATION, PACKAGING

2.5 mg per tablet, 50 tablets in bottle.

STORAGE

Store Mono-Femara at controlled room temperature, away from light and moisture.

DELIVERY TO THE USA

Mono-Femara is available for secure and discreet delivery to the USA through authorized suppliers.

LEGAL STATUS

Mono-Femara is a prescription medication. Adherence to local regulations regarding purchase and use is paramount.

Note: This information is for educational purposes only and does not substitute professional medical advice. Consult with a healthcare professional for personalized guidance on the use of Mono-Femara.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Beligas Pharmaceuticals
USA

EXTERNAL LINKS

• Letrozole Wiki, wikipedia.org
• Letrozole Uses, Side Effects & Warnings, drugs.com
• Letrozole Oral: Uses, Side Effects, Interactions, Pictures, medlineplus.gov.